RESEARCH PAPER

5-Chloroindole: a potent allosteric modulator of the 5-HT₃ receptor

Amy S Newman^{1*}, Nikolaos Batis^{1*}, Gillian Grafton¹, Francesca Caputo^{2,3}, Catherine A Brady¹, Jeremy J Lambert⁴, John A Peters⁴, John Gordon⁵, Keith L Brain², Andrew D Powell^{2†} and Nicholas M Barnes^{1†}

¹Cellular and Molecular Neuropharmacology Research Group, Clinical and Experimental Medicine, Medical School, University of Birmingham, Edgbaston, Birmingham, UK, ²Clinical and Experimental Medicine, Medical School, University of Birmingham, Edgbaston, Birmingham, UK, ³Department of Neuropharmacology, University of Siena, Siena, Italy, ⁴Division of Neuroscience, Medical Research and Education Institutes, Ninewells Hospital and Medical School, The University of Dundee, Dundee, UK, and ⁵Immunity and Infection, Medical School, University of Birmingham, Edgbaston, Birmingham UK

Correspondence

Nicholas M Barnes, Cellular and Molecular Neuropharmacology Research Group, Clinical and Experimental Medicine, Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. E-mail: n.m.barnes@bham.ac.uk

*Joint first authors.

†Equal senior authors.

Keywords

5-HT₃ receptor; ligand-gated ion channel; allosteric modulation

Received

25 October 2012

Revised

8 January 2013

Accepted

16 February 2013

BACKGROUND AND PURPOSE

The 5-HT₃ receptor is a ligand-gated ion channel that is modulated allosterically by various compounds including colchicine, alcohols and volatile anaesthetics. However the positive allosteric modulators (PAMs) identified to date have low affinity, which hinders investigation because of non-selective effects at pharmacologically active concentrations. The present study identifies 5-chloroindole (Cl-indole) as a potent PAM of the 5-HT₃ receptor.

EXPERIMENTAL APPROACH

5-HT₃ receptor function was assessed by the increase in intracellular calcium and single-cell electrophysiological recordings in HEK293 cells stably expressing the h5-HT_{3A} receptor and also the mouse native 5-HT₃ receptor that increases neuronal contraction of bladder smooth muscle.

KEY RESULTS

Cl-indole (1–100 μM) potentiated agonist (5-HT) and particularly partial agonist [(S)-zacopride, DDP733, RR210, quipazine, dopamine, 2-methyl-5-HT, SR57227A, *meta* chlorophenyl biguanide] induced h5-HT_{3A} receptor-mediated responses. This effect of Cl-indole was also apparent at the mouse native 5-HT₃ receptor. Radioligand-binding studies identified that Cl-indole induced a small (~two-fold) increase in the apparent affinity of 5-HT for the h5-HT_{3A} receptor, whereas there was no effect upon the affinity of the antagonist, tropisetron. Cl-indole was able to reactivate desensitized 5-HT₃ receptors. In contrast to its effect on the 5-HT₃ receptor, Cl-indole did not alter human nicotinic α7 receptor responses.

CONCLUSIONS AND IMPLICATIONS

The present study identifies Cl-indole as a relatively potent and selective PAM of the 5-HT₃ receptor; such compounds will aid investigation of the molecular basis for allosteric modulation of the 5-HT₃ receptor and may assist the discovery of novel therapeutic drugs targeting this receptor.

LINKED ARTICLES

Recent reviews on allosteric modulation can be found at:

Kenakin, T (2013). New concepts in pharmacological efficacy at 7TM receptors: IUPHAR Review 2. British Journal of Pharmacology 168: 554–575. doi: 10.1111/j.1476-5381.2012.02223.x

Roche D, Gil D and Giraldo J (2013). Mechanistic analysis of the function of agonists and allosteric modulators: reconciling two-state and operational models. British Journal of Pharmacology 169: 1189–1202. doi: 10.1111/bph.12231

Abbreviations

AM, acetoxymethyl; Cl-indole, 5-chloroindole; E_{5-HT}, reversal potential for 5-HT-evoked current; HEKh5-HT_{3A}, HEK293 cells stably expressing the human 5-HT_{3A} subunit; LGIC, ligand-gated ion channel; mCPBG, *meta* chlorophenyl biguanide; PAMs, positive allosteric modulators

Introduction

The 5-HT₃ receptor mediates fast synaptic neurotransmission in neurons of both the central and peripheral nervous systems (Barnes *et al.*, 2009; Walstab *et al.*, 2010). In addition, the receptor is expressed by a number of other cell types including several subsets of immune cells (e.g. Fiebich *et al.*, 2004; Rinaldi *et al.*, 2010). Various antagonists of the 5-HT₃ receptor offer benefit to patients experiencing nausea and vomiting, most commonly those arising from aggressive anti-cancer chemo- and radiation-therapy, or following recovery from general anaesthesia (post-operative nausea and vomiting). In addition, 5-HT₃ receptor antagonists such as alosetron offer symptomatic relief to patients with irritable bowel syndrome, although rare instances of severe constipation and ischaemic colitis have limited use of these medications (Barnes *et al.*, 2009; Walstab *et al.*, 2010).

At the molecular level, the 5-HT₃ receptor belongs to the Cys-loop ligand-gated ion channel (LGIC) superfamily that also includes nicotinic acetylcholine, GABA_A, strychnine-sensitive glycine receptors and a much less studied Zn²⁺-activated cation channel (Barnes *et al.*, 2009). In common with other superfamily members, the functional receptor is a pentameric complex in which the second transmembrane domain of each subunit lines the transmembrane pore and contributes significantly to the integral ion channel (Boess *et al.*, 1995; Barnes *et al.*, 2009). However, other regions such as the membrane-associated stretch within the C-terminal end of the large second intracellular loop (Kelley *et al.*, 2003; Peters *et al.*, 2005) and the lining of the extracellular domain (Livesey *et al.*, 2011) make important contributions to the permeation pathway.

Five human genes have been identified to date that encode the subunits 5-HT_{3A}-E (Barnes *et al.*, 2009; Walstab *et al.*, 2010; Alexander *et al.*, 2011). Atypical for the Cys-loop superfamily, the 5-HT_{3A} subunit assembles efficiently as a functional homomeric receptor complex that possesses many of the pharmacological and biophysical characteristics of some native 5-HT₃ receptors, particularly those expressed by certain neuroblastoma cell lines (Lambert *et al.*, 1989; Gill *et al.*, 1995). However, not all biophysical characteristics of other native 5-HT₃ receptors, such as those of rodent superior cervical ganglion and hippocampal neurones (Yang *et al.*, 1992; Hussy *et al.*, 1994; Jones and Surprenant, 1994) are mimicked by homomeric 5-HT_{3A} receptors (Fletcher and Barnes, 1998) and incorporation of the 5-HT_{3B} subunit would appear to account for this biophysical diversity (Davies *et al.*, 1999; Dubin *et al.*, 1999; Peters *et al.*, 2005).

The orthosteric 5-HT recognition site is located at subunit interfaces within the extracellular domain (Barnes *et al.*, 2009). In common with other Cys-loop superfamily members, the 5-HT₃ receptor possesses topologically distinct allosteric sites that appear to recognize a diverse array of compounds. These include various alcohols and indole derivatives and colchicine (Parker *et al.*, 1996; Hu *et al.*, 2006; Hu and Lovinger, 2008; Walstab *et al.*, 2010; Davies, 2011). The therapeutic potential of allosteric receptor ligands is increasingly recognized in pharmaceutical research and development due to their ability to modulate receptor function yet retain spatial and temporal control (e.g. Williams *et al.*, 2011).

The best-characterized positive allosteric modulator (PAM), 5-hydroxyindole, has diverse effects on 5HT₃ receptors. Studies show a mix of allosteric and orthosteric effects (Kooyman *et al.*, 1994; Hu and Lovinger, 2008). Indeed, one study failed to show any effect, suggesting that 5-hydroxyindole is a PAM at rodent receptors, with no activity at their human counterpart (Grønlien *et al.*, 2010). Furthermore, 5-hydroxyindole lacks selectivity having a well-described allosteric action on nicotinic $\alpha 7$ receptors. The relatively low affinity (mM) and poor selectivity hampers the utility of the currently characterized PAMs as tools to study their pharmacological impact. In the present study, we report the identification of the 5-substituted indole, 5-chloroindole (Cl-indole; Moretti *et al.*, 1996; Supporting Information Figure S1), as a selective allosteric modulator of the 5-HT₃ receptor that displays micromolar potency.

Materials and methods

Cell culture

HEK293 cells stably expressing the human 5-HT_{3A} subunit (HEKh5-HT_{3A} cells; Brady *et al.*, 2001) were grown in DMEM, supplemented with 10% (v/v) FBS, 1% (v/v) penicillin/streptomycin (10 000 U·mL⁻¹ penicillin and 10 mg·mL⁻¹ streptomycin) and G418 (250 µg·mL⁻¹) and maintained at 37°C, 5% CO₂, 95% air at 95% relative humidity. Approximately 24 h prior to intracellular calcium assays, cells were seeded directly into poly-D-lysine coated, black-walled, clear bottomed, 96-well plates (Costar, Bio-Rad Laboratories Ltd., Hemel Hempstead, UK) at a density of 1 × 10⁵ cells per well. HEK293 cells stably expressing the human $\alpha 7$ nicotinic receptor and the human $\text{ric}3$ protein (HEK $\alpha 7\text{ric}3$; G. Grafton *et al.*, unpubl.) were grown in DMEM supplemented with 10% (v/v) FBS, 10 000 U·mL⁻¹ penicillin, 10 mg mL⁻¹ streptomycin, 250 µg·mL⁻¹ G418 and 250 µg·mL⁻¹ hygromycin B and were maintained as per HEKh5-HT_{3A} cells.

Intracellular Ca²⁺ measurements

Cells were washed with 1 × HBSS (Invitrogen, Paisley, UK) and incubated with fluo-4 acetoxymethyl (AM) ester (2.5 µM; Molecular Probes, Paisley, UK) for 60 min at room temperature. Cells were then washed in HBSS and incubated for a further 30 min (room temperature) prior to assay. Changes in intracellular calcium were measured using a FlexStation (Molecular Devices, Sunnyvale, CA, USA) with fluorescence levels assessed every 3 s. Buffer, or Cl-indole, was added after 20 s, agonist/partial agonist (or antagonist tested for potential emergent agonist activity) was added after 80 s and recordings continued for at least 4 min. In antagonism studies, antagonists were pre-incubated for half an hour prior to analysis.

Radioligand binding

Radioligand-binding assays were performed similar to our previous studies (e.g. Monk *et al.*, 2004). Briefly, HEKh5-HT_{3A} cells were homogenized (Polytron, Fisher Scientific, Loughborough, UK) in Tris/Krebs buffer (in mM; Tris 50.0, NaCl 118.0, KCl 4.75, KH₂PO₄ 1.2, MgSO₄ 1.2, CaCl₂ 2.5, NaHCO₃ 25.0, glucose 11.0, final pH 7.4 adjusted with NaOH) and washed twice by centrifugation (48 000× g; 4°C) before re-suspension in Tris/Krebs buffer. Radioligand-binding assays were per-

formed in triplicate; glass tubes contained 500 μL of competing drug, or vehicle (Tris/Krebs buffer), and 100 μL of [^3H]-granisetron (~ 1 nM for competition studies, or a range of concentrations between 0.1 and 15 nM for saturation studies; ~ 3 TBqmmol $^{-1}$; NEN Life Science Products, PerkinElmer, Seer Green, UK). An aliquot (100 μL) of the cell homogenate was added to initiate binding, which was allowed to proceed at 37°C for 60 min before termination by rapid filtration and washing under vacuum through Whatman GF/B filters, followed by assay of the radioactivity remaining on the filters.

Single-cell electrophysiology

Macroscopic currents were recorded in the whole-cell recording mode of the patch-clamp technique from HEK293 cells cultured on coverslips using infrared DIC (inverted Olympus FV1000 confocal microscope; Olympus KeyMed, Southend on Sea, UK). Cells were superfused at ~ 4 mL·min $^{-1}$ with an extracellular solution (in mM; NaCl 140, KCl 2.8, CaCl $_2$ 1.0, glucose 10, HEPES 10, pH 7.4 adjusted with NaOH). Patch electrodes were pulled from borosilicate glass (o.d. 1.2 mm, i.d. 0.69 mm; Harvard Apparatus, Edenbridge, UK) using a P-97 puller (Sutter, Novato, CA, USA) and filled with intracellular solution consisting of (in mM) 135 CsCl, 2 MgCl $_2$, 10 HEPES, 1 EGTA, 2 Mg-ATP and 0.3 Na-GTP; pH adjusted to 7.3 with KOH (osmolality ~ 285 mOsm). Patch electrodes typically had open tip resistances of 4–7 M Ω . Membrane currents were recorded using an NPI SEC-10 L amplifier (Scientifica, Harpenden, UK), low-pass Bessel filtered at 1 kHz (NL-125; Digitimer Ltd., Welwyn Garden City, UK) and digitized at 10 kHz by a Power 1401 (CED Ltd., Cambridge, UK). Experiments were performed at room temperature with the cells voltage-clamped at -60 mV. Stimulation and data acquisition were controlled using Signal software (version 3; CED).

Agonist-evoked currents were elicited by either pressure ejection (20-kPa; Picospritzer II; General Valve, Fairfield, NJ, USA) of agonist (5-HT 1.0–10 μM , or DDP733 100 nM) from modified patch pipettes placed ~ 30 μm from the recorded cell, or by bath application of 5-HT (1.0 μM).

Neuronal contraction of mouse bladder

Male BALB/c albino mice, aged 8–12 weeks, were killed with a rising CO $_2$ concentration followed by cervical fracture. All experiments were carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and European Communities Council Directive 86/09/EEC. All studies involving animals are reported in accordance with the ARRIVE guidelines for reporting experiments involving animals (Kilkenny *et al.*, 2010; McGrath *et al.*, 2010). The urinary bladder was removed and placed in physiological saline (in mM; NaCl 118.4, NaHCO $_3$ 25.0, NaH $_2$ PO $_4$ 1.13, CaCl $_2$ 1.8, KCl 4.7, MgCl $_2$ 1.3, glucose 11.1 pH and [O $_2$] were regulated by continuously bubbling the solution reservoir with 95% O $_2$ and 5% CO $_2$). Other organs were harvested for experimental use in other projects. Connective tissue surrounding the bladder was first removed before the ventral wall of the bladder was opened longitudinally from the bladder neck to the apex of the dome with the urothelium left intact. Tissue strips (6–8 mm long, 1–2 mm wide) were cut along the craniocaudal axis of the dorsal surface for organ bath studies. Each bladder strip was mounted in a 500 μL organ bath and connected to an isometric transducer (HLT050/D; ADInstruments, Chalgrove, UK)

under an initial tension of 9.8 mN and allowed to equilibrate (i.e. to accommodate under tension) for at least 60 min. Electrical field stimulation was delivered every minute by a Grass S48 stimulator (Grass Instruments, Quincy, MA, USA) with a 0.1 ms pulse width, at 90 V with a 500 ms train duration at a train frequency of 10 Hz. Contraction data were digitized using a Powerlab/4SP data acquisition system using Chart v.4.2.3 software (ADInstruments) and data stored on a Macintosh computer.

Drugs were dissolved to the required concentrations in gassed physiological saline solution, then administered to the strips *via* continuous perfusion using a peristaltic pump. For antagonism studies, ondansetron was allowed a minimum equilibration time of 15 min prior to electrical stimulation and the subsequent application of agonist, or Cl-indole.

Data analysis

Concentration response and radioligand-binding data were analysed by computer-assisted iterative curve fitting according to a three parameter logistic equation (Barnes *et al.*, 1992). Electrophysiological data were analysed using Signal3 and Origin 8 (Silverdale Scientific, Stoke Mandeville, UK). Decay times of the 5-HT $_3$ currents were expressed as the time taken to decay to 50% of the maximum response. Where relevant, statistical differences were identified using a *t*-test (GraphPad Software, La Jolla, CA, USA).

Drugs

Cl-indole, dopamine, 5-HT, quipazine and PNU 282 987 (N-[3(R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide) were from Sigma-Aldrich (Poole, UK). Alosetron, DDP733 (MKC-733, pumosestrag), palonosetron, ramosetron and RR210 [5-chloro-7-methyl-2-(4-methyl-1,4-diazepan-1-yl)benzo(*d*)oxazole] were from AMRI Inc. (Albany, NY, USA; a generous gift from Dr Dave Manning). 2-Methyl-5-HT, *meta* chlorophenyl biguanide (mCPBG), SR57227A [4-amino-(6-chloro-2-pyridyl)-1 piperidine hydrochloride], tropisetron and PNU 120 596 were from Tocris (Bristol, UK). BRL46470 {endo-N-[8-methyl-8-azabicyclo(3,2,1)oct-3y1]-2, 3-dihydro-3, 3-dimethyl-indole-1-carboxamide} was from SmithKline Beecham (Harlow, UK; a generous gift from Dr Tom Blackburn). Ondansetron was from GSK (Stevenage, UK). (S)-Zacopride was from Delalande (Paris, France; a generous gift from Dr Jean-Claude Levy).

Results

5-HT $_3$ receptor agonists increase intracellular calcium in HEK293 cells

The endogenous full agonist, 5-HT (10 nM–10 μM), or a range of structurally diverse partial 5-HT $_3$ receptor agonists [(S)-zacopride, DDP733, RR210, quipazine, dopamine, 2-methyl-5-HT, SR57227A, mCPBG], evoked concentration-dependent increases in intracellular calcium in HEK293 cells (Figure 1; Supporting Information Figures S2 and S3). Maximal responses evoked by the partial agonists ranged from inconsistent responses barely above baseline [$\sim 3\%$ (S)-zacopride] to 89% (mCPBG) of the maximal response to 5-HT (Figure 1; Supporting Information Figures S2 and S3). It was notable that in the continued presence of 5-HT, or partial

Figure 1

Concentration-dependent ability of 5-HT (A) and DDP733 (B) to increase intracellular calcium in HEK293 cells expressing the h5-HT₃A receptor and blockade of such responses by prior incubation with the selective 5-HT₃ receptor antagonist, ondansetron (500 nM). Data representative of at least five independent experiments.

agonists with relatively high intrinsic activity, particularly at the higher concentrations investigated, there was tachyphylaxis of the intracellular calcium response (e.g. Figure 1).

Untransfected HEK 293 cells did not respond to either 5-HT (10 μM), or DDP733 (1 μM), although these cells responded to the muscarinic acetylcholine receptor agonist, carbachol (1 mM; data not shown).

Potentialiation by Cl-indole of the h5-HT₃A receptor-mediated increase in intracellular calcium in HEKh5-HT3A cells

Application of Cl-indole (1–100 μM) potentiated 5-HT responses in a concentration-dependent manner (Figure 2A and B). Cl-indole produced a small potentiation of the peak Ca²⁺ signal and slowed the decay of the Ca²⁺ signal in the response to a maximally effective concentration of 5-HT (3 μM). The effects of Cl-indole on 5-HT-induced Ca²⁺ increases were more pronounced with sub-maximal concentrations of 5-HT (Figure 2). Cl-indole alone did not increase intracellular calcium in HEKh5-HT3A cells.

Cl-indole also induced a concentration-dependent increase in the maximal responses evoked by a range of 5-HT₃ receptor partial agonists (Figure 2C and D and Supporting Information Figures S2 and S3A).

Increases in intracellular calcium in HEKh5-HT3A cells evoked by 5-HT and the partial agonists in the absence and

presence of Cl-indole (10–100 μM) were completely blocked by prior application of the selective antagonists, ondansetron (500 nM; Supporting Information Figure S3B – data for 10 μM Cl-indole not shown) and granisetron (500 nM; data not shown). In contrast to the 5-HT₃ receptor agonists, the selective 5-HT₃ receptor antagonists alosetron, BRL46470, ondansetron, ramosetron, and palonosetron (all individually at 3 μM) did not evoke increases in intracellular calcium in HEKh5-HT3A cells in either the absence, or presence, of Cl-indole (10–100 μM; Supporting Information Figure S4).

Potentialiation by Cl-indole of agonist-evoked currents recorded under voltage-clamp from HEKh5-HT3A cells

At a holding potential of –60 mV, a brief application of 5-HT (10 μM; 100 ms) to HEKh5-HT3A cells elicited a transient inward current (560 ± 130 pA, *n* = 6; Figure 3A). The rising phase was best fitted by a single exponential function with a mean time constant of 0.9 ± 0.1 s and the current decayed slowly back to baseline (*t*₅₀ 2.1 ± 0.4 s). Repeated applications (5 min interval) of 5-HT significantly reduced the amplitude of the inward current, such that by the third application the peak amplitude was approximately one-third of the initial response (Figure 3A). In contrast, 5-HT₃ receptor currents evoked by a 10 ms application of 5-HT (10 μM) at the same frequency were not reduced by repeated stimulation

Figure 2

Concentration-dependent ability of Cl-indole to potentiate responses to 5-HT (A; 0.3 μ M, B; 3.0 μ M) and DDP733 (C; 100 nM) to increase intracellular calcium in HEK293 cells expressing the h5-HT₃A receptor (data representative from 3 to 6 experiments). In A–C, drugs were added where indicated by the horizontal bar. D; Cl-indole concentration–responses fitted to a three-parameter logistic equation (100 nM DDP – triangles, 0.3 μ M 5-HT – squares and 3.0 μ M 5-HT – circles and *inset*).

(Figure 3A) and hence this protocol was employed for further investigations.

Superfusion of Cl-indole (10 μ M) did not alter the holding current of 5-HT₃A receptor expressing HEK 293 cells, nor did the compound alter the amplitude (control 411 ± 107 pA, Cl-indole 399 ± 106 pA; $n = 6$; $P = 0.86$) or rise time (control 76 ± 16 ms, Cl-indole 110 ± 40 ms; $n = 6$; $P = 0.31$) of 5-HT (10 μ M)-induced currents (Figure 3B). However, Cl-indole significantly increased the decay time for 5-HT₃ receptor-mediated currents (control $t_{50} = 2.8 \pm 0.7$ s, Cl-indole $t_{50} = 12.2 \pm 2.5$ s; $n = 6$; $P = 0.005$); the effect of Cl-indole on decay rate was partially reversible after washout ($t_{50} = 6.3 \pm 1.0$ s; $P = 0.04$; Figure 3B).

The selective 5-HT₃ receptor antagonist, ondansetron (100 nM), completely blocked the activation of 5-HT₃ receptors by 5-HT (10 μ M) in both the absence and presence of Cl-indole (10 μ M). The effect of ondansetron was reversible upon washout with subsequent application of 5-HT evoking inward current, which was modulated by Cl-indole (Figure 4A).

To assess whether Cl-indole affected the ionic permeability of the h5-HT₃A receptor, the I–V relationship of the mac-

roscopic current response to 5-HT was constructed by a voltage ramp (–100 to +60 mV) recorded at the peak of the current response to bath-applied 5-HT (1.0 μ M; 15 s). The reversal potential (E_{5-HT}) in the presence and absence of Cl-indole (10 μ M) was -2.2 ± 3.1 and -0.5 ± 2.9 mV, respectively ($n = 6$, $P = 0.74$) (Figure 4B), suggesting that Cl-indole does not grossly affect the ionic permeability of h5-HT₃A receptors. The peak 5-HT current recorded at –60 mV was significantly increased by Cl-indole (Control 265.8 ± 127.8 pA; Cl-indole 1430.8 ± 362.9 pA; $n = 5$, $P < 0.05$).

Application of the 5-HT₃ receptor partial agonist, DDP733 (100 nM; 100 ms), evoked a relatively small inward current (149 ± 58 pA, $n = 6$; Figure 4C) which had a slow rise time (10.2 ± 3.2 s) and slow decay time (46.5 ± 10.5 s). Superfusion of Cl-indole (10 μ M), significantly increased the amplitude of DDP733-induced currents (912 ± 272 pA; $P < 0.05$; Figure 4C) and slowed the rise time (18.6 ± 3.9 s; $P < 0.005$). Cl-indole also prolonged the decay rate of DDP733-induced currents (137 ± 35 s; $P < 0.01$; Figure 4C). The effect of Cl-indole upon DDP733-evoked amplitude, rise time and decay rate was fully reversed by washout of Cl-indole (33.1 ± 6.5 pA, 11.6 ± 3.9 s, 52 ± 20 s, respectively).

Figure 3

A: ability of repeated application of 5-HT (10 μM) for 100 ms (i) and 10 ms (ii) to evoke responses from voltage-clamped HEK293 cells expressing the h5-HT₃A receptor. Traces are representative of at least three independent experiments, numbers represent the traces corresponding to the application number of the 5-HT. Data in histograms represent mean ± SEM, $n = 5-6$. B: ability of 5-HT (10 μM applied for 10 ms) in the absence (control) and presence of Cl-indole (10 μM, grey trace) to evoke responses from voltage-clamped HEK293 cells expressing the h5-HT₃A receptor (i) with histograms displaying impact upon decay time (ii), amplitude (iii) and rise time (iv); the right hand column in each of these histograms represents results after wash-out of Cl-indole. * $P < 0.05$, ** $P < 0.01$.

Modulation of neuronally mediated contraction of mouse bladder

To investigate the ability of Cl-indole to modulate native 5-HT₃ receptors, the 5-HT₃ receptor-mediated increase in bladder smooth muscle 'twitch' was investigated (Chetty *et al.*, 2007). Under control conditions, electrical field stimulation induced a tetrodotoxin (100 nM)-sensitive contraction of the muscle strips. Using a sub-maximal stimulus protocol (six pulses at 10 Hz), consistent contraction amplitudes were obtained when the stimuli were delivered 1 min apart. The selective 5-HT₃ receptor agonist, mCPBG (3.0 μM), transiently increased the amplitude of contraction, reaching a peak increase of $20 \pm 4\%$ ($n = 4$ strips; $P < 0.05$), which subsequently declined in the continued presence of mCPBG (30 μM; Figure 5). Cl-indole (30 μM) alone had no effect on the amplitude of contraction ($6 \pm 3\%$; $n = 4$; $P = 0.46$; Figure 5), but subsequent addition of mCPBG (3.0 μM) greatly increased the peak amplitude by $54 \pm 3\%$, an effect that was maintained in the continued presence of mCPBG (30 μM; Figure 5).

In the presence of the 5-HT₃ receptor antagonist ondansetron (500 nM) and subsequent application of Cl-indole (30 μM), mCPBG (3.0 μM) did not significantly increase the amplitude of contraction ($8 \pm 7\%$; $n = 6$; $P = 0.30$; Figure 5Cii, open bars): in the matching set of bladder strips, Cl-indole (30 μM) + mCPBG (3.0 μM) in the absence of ondansetron increased the peak amplitude by $31 \pm 10\%$ ($n = 5$; $P < 0.05$; Figure 5Cii filled bars).

Effect of Cl-indole upon ligand affinity for the h5-HT₃A receptor

Cl-indole (10 μM) had no effect upon saturation data arising from [³H]granisetron (0.1–10 nM) binding the h5-HT₃A receptor expressed by HEK5-HT3A cells ($B_{max} = 1130 \pm 146$ and 1027 ± 66 fmol·mg⁻¹ protein, $pK_d = 8.85 \pm 0.20$ and 8.77 ± 0.16 calculated in the absence and presence of Cl-indole, respectively [mean ± SEM, $n = 3$], $P > 0.05$; non-specific binding defined by ondansetron, 10 μM). In competition studies with 5-HT and the antagonist, tropisetron, Cl-indole (10 μM) increased the apparent affinity of 5-HT for the [³H]granisetron specific binding site in HEK5-HT3A cell homogenates ($P < 0.05$), but did not modify the affinity of tropisetron ($P > 0.05$; Figure 6 and Table 1).

Further characterization of Cl-indole as a PAM

To further characterize the effect of Cl-indole, we examined whether it could re-activate desensitized 5-HT₃ receptors. Prolonged bath application of 5-HT (10 μM) produced a large transient current (2.52 ± 0.75 nA; $n = 4$) that decayed rapidly to $8.9 \pm 4.0\%$ of the peak response. In the continued presence of 5-HT, pressure ejection of Cl-indole (10 μM) elicited an inward current (0.97 ± 0.54 pA; Figure 7).

Previously described PAMs of the 5-HT₃ receptor suffer from a lack of potency and specificity; for example, 5-hydroxyindole, is a PAM of both 5-HT₃ (van Hooft *et al.*, 1997) and nicotinic α7 receptors (Zwart *et al.*, 2002). To estab-

Figure 4

Ability of Cl-indole (10 μ M) to potentiate 5-HT₃ receptor agonist responses. A: The presence of the selective 5-HT₃ receptor antagonist, ondansetron (100 nM), completely prevented a response to 5-HT (10 μ M applied for 10 ms) in the presence of Cl-indole (10 μ M). The effect of ondansetron was partly reversible by wash-out [subsequent response to 5-HT (10 μ M applied for 10 ms; wash)]. Traces are representative of at least three independent experiments. B: I-V plots arising in the presence of 5-HT (1.0 μ M) or 5-HT (1.0 μ M) plus Cl-indole (10 μ M) determined around the peak response (indicated #). Drugs were bath applied for 15 s. Traces are representative of at least three independent experiments. C: DDP733 (100 nM) in the absence and presence of Cl-indole (10 μ M); recordings from voltage-clamped HEK293 cells expressing the h5-HT₃A receptor (i) with histograms displaying impact upon decay time (ii), amplitude (iii) and rise time (iv); the right-hand column in each of these histograms represents results after wash-out of Cl-indole. Traces are representative of at least three independent experiments. Data in histograms represent mean $\pm$ SEM, $n = 5-6$. * $P < 0.05$, ** $P < 0.01$.

Table 1

Impact of Cl-indole (10 μ M) upon the affinity (pK_i) of 5-HT and tropisetron (ICS 205-930; (1*R*,5*S*)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1-methyl-indole-3-carboxylate) and Hill coefficient for the h5-HT₃A receptor radiolabelled with [³H]granisetron

	pK_i	Hill coefficient
5-HT	6.31 $\pm$ 0.03	1.59 $\pm$ 0.21
5-HT + Cl-indole	6.57 $\pm$ 0.03*	1.44 $\pm$ 0.13
Tropisetron	8.50 $\pm$ 0.10	1.00 $\pm$ 0.03
Tropisetron + Cl-indole	8.39 $\pm$ 0.06	0.99 $\pm$ 0.04

Data represents mean $\pm$ SEM from four independent experiments. Effect of Cl-indole * $P < 0.05$.

lish the specificity of the modulation by Cl-indole, we tested its effect on nicotinic $\alpha 7$ receptors stably co-expressed with ric3 in HEK-293 cells (G. Grafton *et al.*, unpubl.). Application of the selective nicotinic $\alpha 7$ agonist, PNU 282 987 (1 μ M), induced a small inward current 38.4 ± 14.0 pA ($n = 5$; Figure 8). While nicotinic $\alpha 7$ currents were potentiated by the PAM, PNU 120 596 (control, 43.1 ± 12.5 pA; PNU 120 596, 1332.2 ± 296.3 pA; $n = 5$ $P < 0.05$), Cl-indole did not modulate

the nicotinic $\alpha 7$ current (27.8 ± 5.8 pA, $P = 0.34$), suggesting that Cl-indole is a selective PAM of 5-HT₃ receptors.

Discussion

The present study demonstrates that Cl-indole is a relatively potent and selective PAM of the h5-HT₃A receptor, with this action appearing to extend to the mouse native 5-HT₃ receptor. Our studies initially measured the 5-HT₃ receptor-mediated increase in intracellular calcium, which demonstrated that HEK5-HT₃A cells possessed a functional h5-HT₃A receptor based on receptor pharmacology with a range of selective and non-selective 5-HT₃ receptor ligands. The pharmacological profile included differential maximal responses by a variety of partial agonists, the majority with recognized sub-maximal intrinsic activities. Further evidence supporting a selective modulation of intracellular calcium *via* the 5-HT₃A receptor came from studies performed in parallel where 5-HT₃ receptor agonists failed to evoke responses in native HEK293 cells.

When applied alone to HEK5-HT₃A cells, Cl-indole did not cause an increase in intracellular calcium yet, in a concentration-dependent manner, potentiated the response to a range of agonists for the 5-HT₃ receptor. It is noteworthy

Figure 5

Cl-indole augments the mCPBG-induced potentiation of the neurogenic contractile response in mouse bladder strips. (A) Sample traces from different bladder strips showing that Cl-indole (30 μ M) augments the mCPBG-induced potentiation of contractile response in mouse bladder strips. (Ai) mCPBG (3.0 μ M) alone only subtly increases the amplitude of contractile force generated following field stimulation. (Aii) In the presence of Cl-indole (30 μ M), mCPBG increases to a greater relative extent the contractile force. For each panel, the black line indicates the neurogenic contraction in the absence of mCPBG, and the grey line indicates the subsequent response in the presence of mCPBG in the same bladder strip. (Ai) and (Aii) show the response of different bladder strips from the same mouse and measured in parallel; the mean amplitudes did not vary significantly amongst the two test groups, although different muscle strips (even from the same animals) showed a range of typical contractile forces. (Bi) Field stimulation of mouse bladder strips (open bars) is subtly augmented by mCPBG (3.0 μ M), an effect that shows tachyphylaxis (i.e. the plateau contractile amplitude in the continued presence of mCPBG is lower than the peak response). This effect is reversible upon removing mCPBG (washout). (Bii, Ci) In the presence of Cl-indole (30 μ M), the peak response to mCPBG (3.0 μ M) was potentiated and the tachyphylaxis was prevented (closed bars). The effect of Cl-indole was only partially reversed on wash. Cl-indole alone had no significant effect on contraction. (Cii) Responses to mCPBG (3.0 μ M) in the presence of Cl-indole were blocked by the 5-HT₃ receptor antagonist ondansetron (open bar). * P < 0.05 compared with vehicle, ** P < 0.05 compared with mCPBG response in the absence of Cl-indole.

that the efficacy of Cl-indole was strongly agonist-dependent. Thus, at maximally effective concentrations of the agonists, Cl-indole promoted only a small percentage increase in the maximal effect of the full agonist 5-HT, yet responses by agonists with lower intrinsic activity for the 5-HT₃ receptor, were potentiated to a much greater degree. Thus in the presence of Cl-indole, all of the partial 5-HT₃ receptor agonists tested in the present study ((S)-zacopride, DDP733, dopamine, mCPBG, 2-methyl-5-HT, quipazine, RR 210, SR5727A; Richardson *et al.*, 1985; Neijt *et al.*, 1986; Kilpatrick *et al.*, 1990; Bachy *et al.*, 1993; Downie *et al.*, 1995; Yamazaki *et al.*, 1996; Evangelista, 2007) evoked considerably larger responses.

It is now appreciated that 5-HT₃ receptor antagonists can have contrasting characteristics. For example, palonosetron

binds with positive cooperativity (Rojas *et al.*, 2008) as do 5-HT₃ receptor agonists, including most with low intrinsic activity (e.g. Barnes *et al.*, 1992). In addition, palonosetron evokes some receptor internalization that is less apparent with ondansetron and granisetron (Rojas *et al.*, 2010). Another atypical 5-HT₃ receptor antagonist, BRL46470, has an enhanced binding capacity to recombinant 5-HT_{3A} receptors (Steward *et al.*, 1995). However, in the present study both palonosetron and BRL46470 behaved as other 'classical' 5-HT₃ receptor antagonists (aloseptron, ondansetron, ramoseptron) by not displaying agonist activity even in the presence of a maximal concentration of Cl-indole as assessed by measurements of intracellular calcium in HEK293A cells. This directly contrasts with the ability of Cl-indole to elicit robust 5-HT₃ receptor mediated responses from the low intrinsic

Figure 6

Impact of Cl-indole (10 μ M; filled symbols) on the ability of 5-HT (circles) and tropisetron (squares) to compete for specific [3 H]granisetron binding to HEK293 cells expressing the h5-HT $_3$ A receptor. Data represent mean from four independent experiments.

Figure 7

Characterization of Cl-indole. Prolonged bath application of 5-HT (10 μ M) induced an inward current through 5-HT $_3$ A receptors which rapidly and completely desensitized. Subsequent picospritzer application of 10 μ M Cl-indole (1 s, 20 psi; denoted by arrow) revealed a smaller inward current.

activity partial agonists in the same experimental paradigm [e.g. (S)-zacopride, which has previously been designated an antagonist (Smith *et al.*, 1988)]. Such findings suggest that the atypical characteristics of the 5-HT $_3$ receptor ligands, palonosetron and BRL46470, are not attributable to a low level of intrinsic activity for the h5-HT $_3$ A receptor. In contrast, the atypical characteristics of (S)-zacopride in compari-

Figure 8

Cl-indole does not act as a positive allosteric modulator of nicotinic $\alpha 7$ channels. (Ai) Pressure ejection of the nicotinic $\alpha 7$ agonist, PNU 282 987 (1 μ M, 3 s, 20 psi; PNU agonist), evoked an inward current in an $\alpha 7$ /Ric3 cell line (black line) that was not modulated by Cl-indole (grey trace). (Aii) mean data ($\pm$ SEM) showed no significant alteration of nicotinic $\alpha 7$ currents by Cl-indole ($n = 5$). (B) Nicotinic $\alpha 7$ receptor currents evoked by the nicotinic $\alpha 7$ agonist, PNU 282 987, were significantly potentiated by the nicotinic $\alpha 7$ PAM, PNU 120 596 (PNU PAM). Where relevant, allosteric modulators (Cl-indole or PNU 120 596) were bath applied for 10 min prior to application of agonist and were present for the remainder of the recording.

son with other selective 5-HT $_3$ receptor antagonists (e.g. Barnes *et al.*, 1990) may be attributed to a partial agonist action upon the 5-HT $_3$ receptor.

Patch clamp recordings using HEK293A cells demonstrated that Cl-indole potentiated h5-HT $_3$ A receptor mediated responses, particularly the maximal responses evoked by the partial agonist DDP733 in comparison to 5-HT. This effect of Cl-indole was not associated with change in the driving force for the 5-HT $_3$ receptor mediated current as the reversal potential (E_{5-HT}) was unchanged in the presence of Cl-indole.

To determine whether the action of Cl-indole translated from recombinant to native 5-HT $_3$ receptors, we investigated the effect of the compound upon the previously described 5-HT $_3$ receptor mediated increase in the neurogenic contraction of the mouse urinary bladder (Chetty *et al.*, 2007). Due to the presence of 5-HT receptors other than those of the 5-HT $_3$ receptor subtype in this preparation (Chetty *et al.*, 2007), a just-maximal concentration of the selective 5-HT $_3$ receptor agonist, mCPBG, which behaves as a full agonist in this preparation, was employed (Chetty *et al.*, 2007). While mCPBG alone caused a small increase in the amplitude of nerve-stimulation evoked contraction, this effect showed marked tachyphylaxis consistent with 5-HT $_3$ receptor desensitization. Similar to the results obtained with recombinant 5-HT $_3$ receptors, Cl-indole potentiated mCPBG increases in

the neurogenic contraction of the mouse urinary bladder and prevented the tachyphylaxis. Responses to mCPBG in the absence or presence of Cl-indole were prevented by the inclusion of ondansetron (500 nM). Together with the data from HEK5-HT_{3A} cells, these observations suggest that Cl-indole acts similarly on native and heterologously expressed 5-HT₃ receptors. In contrast to reports that 5-hydroxyindole is a PAM at rodent 5-HT₃ receptors but not at human receptors (Grønlien *et al.*, 2010), Cl-indole evoked equivalent responses in both species.

5-substituted indoles, such as 5-hydroxyindole, have been long recognized as PAMs of 5-HT₃ receptors. However several reports indicate that 5-hydroxyindole has both orthosteric and allosteric binding activities (Kooyman *et al.*, 1994; Hu and Lovinger, 2008) suggesting at least two binding sites, one of which may overlap the orthosteric site. Furthermore, 5-hydroxyindole has allosteric effects on the nicotinic $\alpha 7$ receptor (Bertrand and Gopalakrishnan, 2007) and one report suggests that 5-hydroxyindole is a PAM at rodent but not human receptors (Grønlien *et al.*, 2010). These studies cast considerable doubt on 5-hydroxyindole's selectivity and its mixed mode of action renders its use as a pharmacological tool problematical. In the present study we demonstrated, that unlike 5-hydroxyindole, Cl-indole is not an allosteric modulator of nicotinic $\alpha 7$ receptors highlighting the selectivity of Cl-indole over 5-hydroxyindole. Although closely related structures, Cl-indole exhibits a higher potency and selectivity than 5-hydroxyindole, making it a more attractive pharmacological tool for the exploration of the allosteric modulation of the 5-HT₃ receptor.

In conclusion, the present study has identified Cl-indole as a relatively potent and selective PAM of the 5-HT₃ receptor. Availability of such compounds will aid investigation of the molecular basis for allosteric modulation of the 5-HT₃ receptor to help the discovery of novel therapeutic drugs targeting this receptor.

Acknowledgement

Funding from the University of Birmingham (NMB) is gratefully acknowledged.

Conflict of interest

Authors declare that they have not any conflict of interest.

References

- Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th edition (2009). Br J Pharmacol 164 (Suppl. 1): S1–S324.
- Bachy A, Héaulme M, Giudice A, Michaud JC, Lefevre IA, Souilhac J *et al.* (1993). SR 57227A: a potent and selective agonist at central and peripheral 5-HT₃ receptors *in vitro* and *in vivo*. Eur J Pharmacol 237: 299–309.
- Barnes JM, Barnes NM, Costall B, Domeney AM, Kelly ME, Naylor RJ (1990). The differential activities of (R+) and (S-)Zacopride as 5-HT₃ receptor antagonists. Pharmacol Biochem Behav 37: 717–727.
- Barnes JM, Barnes NM, Costall B, Jagger SM, Naylor RJ, Robertson DW *et al.* (1992). Agonist interactions with 5-HT₃ receptor recognition sites in the rat entorhinal cortex labelled by structurally diverse radioligands. Br J Pharmacol 105: 500–504.
- Barnes NM, Hales TG, Lummis SC, Peters JA (2009). The 5-HT₃ receptor – the relationship between structure and function. Neuropharmacology 56: 273–284.
- Bertrand D, Gopalakrishnan M (2007). Allosteric modulation of nicotinic acetylcholine receptors. Biochem Pharmacol 74: 1155–1163.
- Boess FG, Beroukhim R, Martin IL (1995). Ultrastructure of the 5-hydroxytryptamine₃ receptor. J Neurochem 64: 1401–1405.
- Brady CA, Stanford IM, Ali I, Lin L, Williams JM, Dubin AE *et al.* (2001). Pharmacological comparison of human homomeric 5-HT_{3A} receptors versus heteromeric 5-HT_{3A/3B} receptors. Neuropharmacology 41: 282–284.
- Chetty N, Coupar IM, Chess-Williams R, Kerr KP (2007). Demonstration of 5-HT₃ receptor function and expression in the mouse bladder. Naunyn Schmiedebergs Arch Pharmacol 375: 359–368.
- Davies PA (2011). Allosteric modulation of the 5-HT₃ receptor. Curr Opin Pharmacol 11: 75–80.
- Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG *et al.* (1999). The 5-HT_{3B} subunit is a major determinant of serotonin-receptor function. Nature 397: 359–363.
- Downie DL, Hope AG, Belevi D, Lambert JJ, Peters JA, Bentley KR *et al.* (1995). The interaction of trichloroethanol with murine recombinant 5-HT₃ receptors. Br J Pharmacol 114: 1641–1651.
- Dubin AE, Huvar R, D'Andrea MR, Pyati J, Zhu JY, Joy KC *et al.* (1999). The pharmacological and functional characteristics of the serotonin 5-HT_{3A} receptor are specifically modified by a 5-HT_{3B} receptor subunit. J Biol Chem 274: 30799–30810.
- Evangelista S (2007). Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease. Curr Opin Investig Drugs 8: 416–422.
- Fiebich BL, Akundi RS, Seidel M, Geyer V, Haus U, Müller W *et al.* (2004). Expression of 5-HT_{3A} receptors in cells of the immune system. Scand J Rheumatol Suppl 119: 9–11.
- Fletcher S, Barnes NM (1998). Desperately seeking subunits: are native 5-HT₃ receptors really homomeric complexes? Trends Pharmacol Sci 19: 212–215.
- Gill CH, Peters JA, Lambert JJ (1995). An electrophysiological investigation of the properties of a murine recombinant 5-HT₃ receptor stably expressed in HEK 293 cells. Br J Pharmacol 114: 1211–1221.
- Grønlien JH, Ween H, Thorin-Hagene K, Cassar S, Li J, Briggs CA *et al.* (2010). Importance of M2-M3 loop in governing properties of genistein at the $\alpha 7$ nicotinic acetylcholine receptor inferred from $\alpha 7/5\text{-HT}_{3A}$ chimera. Eur J Pharmacol 647: 37–47.
- van Hooft JA, van der Haar E, Vijverberg HPM (1997). Allosteric potentiation of the 5-HT₃ receptor-mediated ion current in N1E-115 neuroblastoma cells by 5-hydroxyindole and analogues. Neuropharm 36: 649–653.
- Hu XQ, Lovinger DM (2008). The L293 residue in transmembrane domain 2 of the 5-HT_{3A} receptor is a molecular determinant of allosteric modulation by 5-hydroxyindole. Neuropharmacology 54: 1153–1165.

- Hu XQ, Hayrapetyan V, Gadhiya JJ, Rhubottom HE, Lovinger DM, Machu TK (2006). Mutations of L293 in transmembrane two of the mouse 5-hydroxytryptamine_{3A} receptor alter gating and alcohol modulatory actions. *Br J Pharmacol* 148: 88–101.
- Hussy N, Lukas W, Jones KA (1994). Functional properties of a cloned 5-hydroxytryptamine ionotropic receptor subunit: comparison with native mouse receptors. *J Physiol* 481: 311–323.
- Jones KA, Surprenant A (1994). Single channel properties of the 5-HT₃ subtype of serotonin receptor in primary cultures of rodent hippocampus. *Neurosci Lett* 174: 133–136.
- Kelley SP, Dunlop JJ, Kirkness EF, Lambert JJ, Peters JA (2003). A cytoplasmic region determines single-channel conductance in 5-HT₃ receptors. *Nature* 424: 321–324.
- Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). NC3Rs Reporting Guidelines Working Group. *Br J Pharmacol* 160: 1577–1579.
- Kilpatrick GJ, Butler A, Burridge J, Oxford AW (1990). 1-(m-chlorophenyl)-biguanide, a potent high affinity 5-HT₃ receptor agonist. *Eur J Pharmacol* 182: 193–197.
- Kooyman AR, van Hooft JA, Vanderheijden PML, Vijverberg HPM (1994). Competitive and non-competitive effects of 5-hydroxyindole on 5-HT₃ receptors in N1E-115 neuroblastoma cells. *Br J Pharmacol* 112: 541–546.
- Lambert JJ, Peters JA, Hales TG, Dempster J (1989). The properties of 5-HT₃ receptors in clonal cell lines studied by patch-clamp techniques. *Br J Pharmacol* 97: 27–40.
- Livesey MR, Cooper MA, Lambert JJ, Peters JA (2011). Rings of charge within the extracellular vestibule influence ion permeation of the 5-HT_{3A} receptor. *J Biol Chem* 286: 16008–16017.
- McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. *Br J Pharmacol* 160: 1573–1576.
- Monk SA, Williams JM, Hope AG, Barnes NM (2004). Identification and importance of N-glycosylation of the human 5-hydroxytryptamine_{3A} receptor subunit. *Biochem Pharmacol* 68: 1787–1796.
- Moretti G, Quartarone G, Tassan A, Zingales A (1996). 5-Amino- and 5-chloro-indole as mild steel corrosion inhibitors in 1N sulphuric acid. *Electrochim Acta* 41: 1971–1980.
- Neijt HC, Vijverberg HPM, van den Bercken J (1986). The dopamine response in mouse neuroblastoma cells is mediated by serotonin 5-HT₃ receptors. *Eur J Pharmacol* 127: 217–274.
- Parker RM, Bentley KR, Barnes NM (1996). Allosteric modulation of 5-HT₃ receptors: focus on alcohols and anaesthetic agents. *Trends Pharmacol Sci* 17: 95–99.
- Peters JA, Hales TG, Lambert JJ (2005). Molecular determinants of single-channel conductance and ion selectivity in the Cys-loop family: insights from the 5-HT₃ receptor. *Trends Pharmacol Sci* 26: 587–594.
- Richardson BP, Engel G, Donatsch P, Stadler PA (1985). Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. *Nature* 316: 126–131.
- Rinaldi A, Chiaravalli AM, Mian M, Zucca E, Tibiletti MG, Capella C *et al.* (2010). Serotonin receptor 3A expression in normal and neoplastic B cells. *Pathobiology* 77: 129–135.
- Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J *et al.* (2008). Palonosetron exhibits unique molecular interactions with the 5-HT₃ receptor. *Anesth Analg* 107: 469–478.
- Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB *et al.* (2010). Palonosetron triggers 5-HT₃ receptor internalization and causes prolonged inhibition of receptor function. *Eur J Pharmacol* 626: 193–199.
- Smith WW, Sancilio LF, Owerer-Atepo JB, Naylor RJ, Lambert L (1988). Zacopride, a potent 5-HT₃ antagonist. *J Pharm Pharmacol* 40: 301–302.
- Steward LJ, Ge J, Bentley KR, Barber PC, Hope AG, Lambert JJ *et al.* (1995). Evidence that the atypical 5-HT₃ receptor ligand, [³H]-BRL46470, labels additional 5-HT₃ binding sites compared to [³H]-granisetron. *Br J Pharmacol* 116: 1781–1788.
- Walstab J, Rappold G, Niesler B (2010). 5-HT₃ receptors: Role in disease and target of drugs. *Pharmacol Ther* 128: 146–169.
- Williams DK, Wang J, Tabe A (2011). Positive allosteric modulators as an approach to nicotinic acetylcholine-targeted therapeutics: advantages and limitations. *Biochem Pharmacol* 82: 915–930.
- Yamazaki S, Yano T, Tabe A (1996). Species differences in the intrinsic activity of MKC-733 for 5-HT₃ receptor. *Jpn J Pharmacol* 71: 62P.
- Yang J, Mathie A, Hille B (1992). 5-HT₃ receptor channels in dissociated rat superior cervical ganglion neurons. *J Physiol* 448: 237–256.
- Zwart R, De Filippi G, Broad LM, Mcphie GI, Pearson KH, Baldwinson T *et al.* (2002). 5-hydroxyindole potentiates human alpha 7 nicotinic receptor mediated responses and enhances acetylcholine-induced glutamate release in cerebellar slices. *Neuropharm* 43: 374–384.

Supporting information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

Figure S1 Structure of Cl-indole.

Figure S2 Concentration-dependent ability of various 5-HT₃ receptor agonists to induce increases in intracellular calcium in HEK293 cells expressing the h5-HT_{3A} receptor in the absence and presence of Cl-indole (10 μM). Data represent mean ± SEM, *n* = 3–6.

Figure S3 Ability of Cl-indole (10, 30 and 100 μM) to potentiate the action of various 5-HT₃ receptor agonists (A) to increase intracellular calcium in HEK293 cells expressing the h5-HT_{3A} receptor and the blockade of the response by the selective 5-HT₃ receptor antagonist, ondansetron (500 nM) (B) 5-HT (3.0 μM), (S)-zacopride (1.0 μM), DDP 733 (1.0 μM), RR210 (1.0 μM), quipazine (30 nM), dopamine (300 μM), SR57227A (1.0 μM), mCPBG (1.0 μM) and 2-methyl-5-HT (10 μM). Data represent mean % response compared with 5-HT ± SEM (*n* = 3–15). Effect of Cl-indole **P* < 0.05, ***P* < 0.01, ****P* < 0.001; antagonism by ondansetron *P* < 0.01 in all instances except compared with (S)-zacopride alone.

Figure S4 Failure of Cl-indole (10, 30 and 100 μM) to induce responses from various 5-HT₃ receptor antagonists assessed by intracellular calcium in HEK293 cells expressing the h5-HT_{3A} receptor. 5-HT, full agonist for comparison, and the antagonists; ramosetron, palonosetron, BRL46470, ondansetron, alosetron and tropisetron (all 3.0 μM). Data represent mean % response compared with 5-HT ± SEM (*n* = 3–8).